Jan. 5 Quick Takes: Eventide leads mega-round by Korro
Plus Saliogen raises $115M series B and updates from DNA Script, Chance, RemeGen, AffaMed, Ray, Edgewise
Korro Bio Inc. raised a $116 million series B round to advance its RNA editing platform, enable clinical development of its lead program for alpha-1 antitrypsin deficiency, and expand its pipeline for other diseases. The round was led by Eventide Asset Management with backing from new investors including Fidelity Management & Research Co., Invus, Point72, Verition Fund Management, Monashee Investment Management and Sixty Degree Capital; all series A investors participated: Atlas Venture, NEA, Wu Capital, Qiming Venture Partners USA, Citadel’s Surveyor Capital, Cormorant Asset Management, MP Healthcare Venture Management and Alexandria Venture Investments.
GordonMD Global Investments and EPIQ Capital Group co-led a $115 million series B round by Saliogen Therapeutics Inc. Fellow new investors included Fidelity, funds and accounts affiliated with T. Rowe Price Associates, D1 Capital Partners, SymBiosis, the Cystic Fibrosis Foundation and the Foundation Fighting Blindness’ venture arm, RD Fund. PBM Capital, which led the Gene Coding platform company’s $20 million series A round last March, also participated. Craig Gordon joined the board...
BCIQ Company Profiles
AffaMed Therapeutics (Shanghai) Co. Ltd.
Hangzhou Chance Pharmaceuticals Co. Ltd.